CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
MediWound develops innovative wound care solutions, focusing on EscharEx®, a bioactive therapy designed to effectively treat chronic wounds like Diabetic Foot Ulcers. This non-surgical treatment uses proteolytic enzymes to safely remove necrotic tissue, promoting faster healing without harming healthy tissue.
INTRODUCTION:
MediWound develops wound care solutions, for chronic wounds and severe burns.
The Company’s leading drug candidate under development and the subject of this EIC Accelerator project is EscharEx®, a groundbreaking bioactive therapy specifically targeting the debridement of Diabetic Foot Ulcers (DFUs) and other challenging chronic wounds.
EscharEx is poised to revolutionize the standard of care (SOC) that for many patients is ineffective.
EscharEx - A GAME-CHANGER IN CHRONIC WOUND CAR…
MediWound Ltd.
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
Guests see up to 5 keywords.
